Lisa Vermunt

2.8k total citations
44 papers, 876 citations indexed

About

Lisa Vermunt is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Lisa Vermunt has authored 44 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 20 papers in Psychiatry and Mental health and 11 papers in Molecular Biology. Recurrent topics in Lisa Vermunt's work include Alzheimer's disease research and treatments (20 papers), Dementia and Cognitive Impairment Research (19 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Lisa Vermunt is often cited by papers focused on Alzheimer's disease research and treatments (20 papers), Dementia and Cognitive Impairment Research (19 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Lisa Vermunt collaborates with scholars based in Netherlands, United States and Spain. Lisa Vermunt's co-authors include Erik M. M. Manders, Paul J. Lucassen, Harm J. Krugers, Charlotte A. Oomen, Marian Joëls, Felisa N. van Hasselt, Philip Scheltens, Charlotte E. Teunissen, Wiesje M. van der Flier and Pieter Jelle Visser and has published in prestigious journals such as Nature Communications, Journal of Neuroscience and Brain.

In The Last Decade

Lisa Vermunt

39 papers receiving 864 citations

Peers

Countries citing papers authored by Lisa Vermunt

Since Specialization

Citations

This map shows the geographic impact of Lisa Vermunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Vermunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Vermunt more than expected).

Fields of papers citing papers by Lisa Vermunt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Vermunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Vermunt. The network helps show where Lisa Vermunt may publish in the future.

Co-authorship network of co-authors of Lisa Vermunt

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Vermunt. A scholar is included among the top collaborators of Lisa Vermunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Vermunt. Lisa Vermunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia 2025 ·Molecular Neurodegeneration ·(unknown), Lisa Vermunt, Carel F.W. Peeters, Emma L. van der Ende, (unknown), Lieke Meeter, (unknown), Harro Seelaar, John C. van Swieten, William T. Hu, Alberto Lleó, Daniel Alcolea, Sebastiaan Engelborghs, Anne Sieben, Alice Chen‐Plotkin, David J. Irwin, Wiesje M. van der Flier, Yolande A.L. Pijnenburg, Charlotte E. Teunissen, Marta del Campo	1
2	CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer’s disease patients 2025 ·Alzheimer s Research & Therapy ·(unknown), Everard G.B. Vijverberg, (unknown), Sjors G. J. G. In ‘t Veld, Manuel Avilés, (unknown), (unknown), Allerdien Visser, Wiesje M. van der Flier, Frederik Barkhof, Marta del Campo, Martijn C. Schut, Alexandre Bejanin, Daniel Alcolea, Charlotte E. Teunissen, Lisa Vermunt	0
3	TREM2 risk variants and associated endophenotypes in alzheimer’s disease 2025 ·Alzheimer s Research & Therapy ·Janna I.R. Dijkstra, Lisa Vermunt, Vikram Venkatraghavan, (unknown), Emma M. Coomans, Rik Ossenkoppele, Elsmarieke van de Giessen, Marc Hulsman, (unknown), Wiesje M. van der Flier, Sietske A.M. Sikkes, Frederik Barkhof, Betty M. Tijms, Alida A. Gouw, Willem de Haan, Everard G.B. Vijverberg, Yolande A.L. Pijnenburg, Henne Holstege, Charlotte E. Teunissen, (unknown)	3
4	Neurofilament light chain improves clinical prognostic models for Guillain-Barré syndrome 2025 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Linda W.G. Luijten, (unknown), Eveline Wiegers, Charlotte E. Teunissen, Lisa Vermunt, Pieter A. van Doorn, Ruth Huizinga, Bart C. Jacobs	1
5	Clinical Accuracy of Serum Neurofilament Light to Differentiate Frontotemporal Dementia from Primary Psychiatric Disorders is Age-Dependent 2024 ·American Journal of Geriatric Psychiatry ·(unknown), Sherri Lee Jones, Elham Rahme, (unknown), (unknown), Lisa Vermunt, (unknown), Charlotte E. Teunissen, Yolande A.L. Pijnenburg, Simon Ducharme	13
6	The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases 2024 ·Journal of Neurochemistry ·(unknown), (unknown), Inge M.W. Verberk, Lisa Vermunt, Elly M. Hol, Charlotte E. Teunissen, Sanne Abeln	10
7	Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic 2024 ·Multiple Sclerosis Journal ·(unknown), (unknown), (unknown), Bastiaan Moraal, (unknown), (unknown), Brigit A. de Jong, (unknown), (unknown), Bob W. van Oosten, Nik Sol, Zoé L. E. van Kempen, Lisa Vermunt, (unknown), Eva Strijbis, Bernard M.J. Uitdehaag, Joep Killestein, Charlotte E. Teunissen	6
8	Plasma Neurofilament Light Chain as a Biomarker for Poor Outcome After Aneurysmal Subarachnoid Hemorrhage 2024 ·World Neurosurgery ·(unknown), Maud A. Tjerkstra, Charlotte E. Teunissen, Janneke Horn, Lisa Vermunt, Bert A. Coert, René Post, W. Peter Vandertop, Dagmar Verbaan	1
9	Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review 2024 ·Alzheimer s Research & Therapy ·(unknown), Lisa Vermunt, Arno de Wilde, (unknown), (unknown), Philip Scheltens, Pieter van Bokhoven, Everard G.B. Vijverberg, Charlotte E. Teunissen	7
10	CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease 2023 ·Brain ·Emma L. van der Ende, Sjors G. J. G. In ‘t Veld, (unknown), Sven J. van der Lee, Janna I.R. Dijkstra, (unknown), (unknown), John C. van Swieten, David J. Irwin, Alice Chen‐Plotkin, William T. Hu, Afina W. Lemstra, Yolande A.L. Pijnenburg, Wiesje M. van der Flier, Marta del Campo, Charlotte E. Teunissen, Lisa Vermunt	27
11	CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease 2023 ·Nature Communications ·Marta del Campo, Lisa Vermunt, Carel F.W. Peeters, Anne Sieben, (unknown), Alberto Lleó, Daniel Alcolea, (unknown), Sebastiaan Engelborghs, (unknown), (unknown), Alice Chen‐Plotkin, David J. Irwin, Wiesje M. van der Flier, Afina W. Lemstra, Charlotte E. Teunissen	31
12	Urine as matrix for analysis of neurofilament light chain is not suitable to distinguish frontotemporal dementia from psychiatric diseases 2023 ·Brain Communications ·(unknown), Hans Heijst, Eline A.J. Willemse, Mardien L. Oudega, Lisa Vermunt, Philip Scheltens, Everard G.B. Vijverberg, Yolande A.L. Pijnenburg, Charlotte E. Teunissen	9
13	CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease 2023 ·Alzheimer s & Dementia ·Emma L. van der Ende, Sjors G. J. G. In ‘t Veld, (unknown), (unknown), Janna I.R. Dijkstra, John C. van Swieten, David J. Irwin, Alice Chen‐Plotkin, William T. Hu, Afina W. Lemstra, Yolande A.L. Pijnenburg, Wiesje M. van der Flier, Marta del Campo, Charlotte E. Teunissen, Lisa Vermunt	1
14	Clinical Value of Longitudinal Serum Neurofilament Light Chain in Prodromal Genetic Frontotemporal Dementia 2023 ·Neurology ·Lucia Giannini, Harro Seelaar, Emma L. van der Ende, Jackie M. Poos, Lize C. Jiskoot, Elise G.P. Dopper, Yolande A.L. Pijnenburg, Eline A.J. Willemse, Lisa Vermunt, Charlotte E. Teunissen, John C. van Swieten, Lieke Meeter	9
15	CSF proteome profiling reveals novel specific diagnostic biomarkers for Dementia with Lewy bodies 2022 ·Alzheimer s & Dementia ·Marta del Campo, Lisa Vermunt, Carel F.W. Peeters, (unknown), Alberto Lleó, Daniel Alcolea, (unknown), Alice Chen‐Plotkin, David J. Irwin, Wiesje M. van der Flier, Afina W. Lemstra, Charlotte E. Teunissen	0
16	Dutch Brain Research Registry for study participant recruitment: Design and first results 2021 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Marissa D. Zwan, Wiesje M. van der Flier, (unknown), (unknown), Lisa Vermunt, Roos J. Jutten, Ingrid S. van Maurik, Sietske A.M. Sikkes, Derek Flenniken, (unknown), Michael W. Weiner, Philip Scheltens, Niels D. Prins	33
17	The Alzheimer’s disease drug development landscape 2021 ·Alzheimer s Research & Therapy ·Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, (unknown), Sasja Heetveld, Jeffrey L. Cummings, Philip Scheltens, Everard G.B. Vijverberg	64
18	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer’s Disease: Results from the MOPEAD Project 2021 ·Journal of Alzheimer s Disease ·Anders Wimo, Mark Belger, (unknown), Frank Jessen, (unknown), Milica G. Kramberger, (unknown), Gunilla Johansson, (unknown), (unknown), Lena Sannemann, (unknown), (unknown), Sergi Valero, Lisa Vermunt, (unknown), Bengt Winblad, Pieter Jelle Visser, Marissa D. Zwan, Merçé Boada	6
19	Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical Characteristics 2020 ·Journal of the American Medical Directors Association ·Olin Janssen, Stephanie J. B. Vos, Ron Handels, Lisa Vermunt, Robert Verheij, Frans R.J. Verhey, Hein van Hout, Pieter Jelle Visser, Karlijn J. Joling	8
20	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease 2019 ·NeuroImage Clinical ·Ellen Dicks, Lisa Vermunt, Wiesje M. van der Flier, Pieter Jelle Visser, Frederik Barkhof, Philip Scheltens, Betty M. Tijms	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact